In a report issued on April 28, Brandon Couillard from Jefferies maintained a Hold rating on Repligen (RGEN – Research Report), with a price target of $170.00. The company's shares closed last Monday at $145.50, close to its 52-week low of $138.41. According to TipRanks.com, Couillard is a top 100 analyst with an average return of 24.0% and a 70.3% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Thermo Fisher, and Align Tech. Repligen has an analyst consensus of Strong Buy, with a price target consensus of $227.80. See Insiders’ Hot Stocks on TipRanks >> Repligen's market cap is currently $8.
https://www.tipranks.com/news/blurbs/repligen-rgen-receives-a-hold-from-jefferies?utm_source=advfn.com&utm_medium=referral
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Repligen Charts.
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Repligen Charts.